Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Guo-jiang Hou"'
Publikováno v:
Experimental and Clinical Endocrinology & Diabetes. 125:669-676
EXf, a glucagon-like peptide 1 (GLP-1) receptor agonist, stimulates β-cell proliferation and reduces apoptosis in diabetic animal models, but the underlying mechanisms are not fully understood. We constructed a FoxO1-GFP fusion protein expression pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6929628e3f7028f72f05f39b4fd9daf
https://doi.org/10.1055/s-0043-117048
https://doi.org/10.1055/s-0043-117048
Autor:
Quan Liu, Zhufang Shen, Caina Li, Guo-jiang Hou, Shousheng Yan, Sujuan Sun, Miaomiao Yang, Shuainan Liu, Yi Huan, Dongan Yu
Publikováno v:
Biological & Pharmaceutical Bulletin. 40:1399-1408
GW002 is a recombinant protein engineered by fusing the C-terminal region of human glucagon-like peptide-1 (GLP-1) to the N-terminal region of human serum albumin (HSA) with a peptide linker. This study aims to evaluate its anti-diabetic effects both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b5bb0d11bde9671cb9adfe621e6131
https://doi.org/10.1248/bpb.b17-00169
https://doi.org/10.1248/bpb.b17-00169
Autor:
Shuainan Liu, Ling Li, Quan Liu, Guo-jiang Hou, Jun Peng, Lin-yi Li, Weiping Liu, Zhufang Shen, Sujuan Sun, Li-hui Gao, Yi Huan, Caina Li
Publikováno v:
Biological Trace Element Research. 153:329-339
Vanadium compounds maintain euglycemic effects in diabetic rats long after drug withdrawal and bis(α-furancarboxylato)oxovanadium(IV) (BFOV) possesses potent antidiabetic effects in diabetic rats. Here, we investigated the treatment and posttreatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb9c8589f445bec4cf3716bc12f93e6f
https://doi.org/10.1007/s12011-013-9689-5
https://doi.org/10.1007/s12011-013-9689-5
Autor:
Yi Huan, Sujuan Sun, Guo-jiang Hou, Shuainan Liu, Quan Liu, Caina Li, Lin-yi Li, Zhufang Shen, Shaocong Hou
Publikováno v:
Peptides. 40
EXf is a C-terminally truncated fragment of Exendin-4 with two amino acid substitutions. Previous studies showed that EXf controls plasma glucose level acting as a glucagon-like peptide 1 (GLP-1) receptor agonist. The purpose of this study was to eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ef6506f0055ea927777bc6241cbfcb
https://pubmed.ncbi.nlm.nih.gov/23353893
https://pubmed.ncbi.nlm.nih.gov/23353893
Publikováno v:
Experimental & Clinical Endocrinology & Diabetes; 2017, Vol. 125 Issue 10, p669-676, 8p